The Definitive Industry Forum for
CKD Drug Development

Advance More Personalized Therapies for Rare & Common Kidney Diseases

The surge of clinical breakthroughs in SGLT2s, GLP-1s and ERAs for CKD, significant advancements to strengthen proteinuria and GFR slope as surrogates for long-term outcomes, and a wave of promising new targets in development, has truly lit the fuse on decades of innovative kidney research.

The summit brought together 200+ biopharma stakeholders, from scientific research to clinical development and outcomes, across three days of concentrated discussion, the 6th CKD Drug Development Summit was the definitive forum for KOLs, industry experts, and regulators to concentrate kidney innovation onto the next generation of drug development.

What Was On?

3 Track Conference

IgAN Nephrology Seminar Day

Deep-Dive Workshop Day

Attendees at a conference listening to a presentation

The flagship summit returned for its 6th iteration with an end-to-end program full of unrivalled scientific content across three tracks, perfect for all your teams:  

  • Discovery, pre-clinical & translational  
  • Proof of concept & early clinical  
  • Late clinical, regulatory & outcomes  
Attendees of the CKD Seminar Day discussing in groups at a table

The summit was dedicated to showcasing ground-breaking research into novel targets, pipeline breakthroughs and real-world patient studies with exclusive insights from Novartis, Calliditas, Genentech, Vera Therapeutics, Otsuka, Takeda, Travere and more. 

CKD workshop day attendees in a Q&A session

The summit was specifically designed to address streamlining feasibility of pediatric CKD trials, validating the relevance of proteinuria and eGFR decline in diverse populations, and repositioning AKI at the forefront of R&D.

Scientific Poster Session

10+ Hours of Networking

60+ Expert Speakers

CKD attendees looking at a scientific poster on display at the conference

This allowed participants to showcase groundbreaking research, or understand what your peers have been working on. This was an opportunity to discover the latest innovations in the CKD space with no extra charge.   


CKD attendees networking in a conference room

Networking allowed participants to forge valuable connections and reconnect with industry leaders through drinks receptions, speed networking sessions, lunch briefings, and more. You could have Joined over 200+ CKD experts from various sectors within the biopharma landscape. 

ckd speaker presenting research data at the conference

This summit allowed for the sharing of cutting-edge pipeline updates, promising pediatric trial data and regulatory insights on the evolving landscape of acceptable surrogate endpoints. 

2024 Speakers

Dedicated Content Streams for 2024

Discovery, Preclinical & Translational

Early Clinical Innovation

Late Clinical, Regulatory & Outcomes


  • Navigated complex heterogeneity in CKD populations to identify more precise targets with Novo Nordisk and Maze Therapeutics
  • Discovered more robust and human-relevant in vivo, ex vivo and in vitro kidney models to streamline translational progress with Pfizer, Eli Lilly, CSL Vifor and Janssen
  • Leveraged GWAS, single-cell RNA sequencing, whole exome sequencing and more to discover CKD-specific pathways with Regeneron, University of Michigan and Novo Nordisk


  • Discovered novel prognostic biomarkers for CKD progression and transform proof of-concept studies with Alpine Immune Sciences, AstraZeneca, C-Path and HI-Bio
  • Advanced knowledge of complement activation in glomerular diseases and evaluate the clinical potential of immunomodulatory candidates for CKD and renal transplantation with Novartis, Visterra and Alexion
  • Uncovered recent clinical breakthroughs in regenerative medicine-based approaches to restore glomerular damage, podocyte injury and more with Purespring Therapeutics and Orbsen Therapeutics


  • Navigated clinical practice guidelines and design more efficient GFR decline studies in a rapidly evolving landscape of SGLT2s, GLP-1s and more with Otsuka, Bayer and Eli Lilly
  • Explored innovation in surrogate endpoints, including a novel HCE for broad use across CKD trials with AstraZeneca, Veloxis Pharmaceuticals and University of Utah
  • Strategically analyzed optimal avenues for reimbursement generation post-approval to maximize patient access in a competitive CKD market with HEOR Ltd and CSL Vifor

Attendees Included

Join Like-Minded Attendees

Hear What Our Past Attendees Say

“One of the few events in the calendar which brings together such a large group of world leading experts in kidney drug development from multiple fields, fully focused and dedicated on how to improve the care for patients living with kidney disease.”

Dominik Steubl, Senior Clinical Program Leader, Boehringer Ingelheim

“The power of this Summit comes from both the diversity of topics and the diversity of subject matter experts across Industry, Academia, Health Care Authorities, and Patient Groups.”

Manish Maski, Head, Global Rare Nephrology Medical Affairs, Sanofi

“A one-of-a-kind unique blend of leaders in the Nephrology community, industry and science discussing exciting advances in biology and treatment of kidney diseases.”

Dermot Reilly, Director, Genetics & Translational Biology, Johnson & Johnson

Our 2024 Partners

george clinical
Antaros Medical
ENYO Pharma_Logo_No background (002)
chinook_logo (002)
Logo Physiogenex

Download Event Guide

CKD Brochure Page 1 EB2

Other Events in the Series